Novo Nordisk's stock fell over 16% after its next-generation obesity drug CagriSema failed to meet efficacy goals in clinical trials, trailing Eli Lilly's Zepbound. This significant setback raises concerns about Novo’s ability to maintain its market position amid increasing competition and pricing pressures. In response, the company plans to implement substantial price cuts for its GLP-1 drugs, a move that may help regain market share but also raises fears about profitability.
“"The market has chosen Lilly as the winner," says @Mizuho's Jared Holz after Novo Nordisk's weight loss drug fails to match Eli Lilly’s in trial.”
“Novo Nordisk's next-gen obesity drug failed to meet efficacy goals in clinical tries, losing out to Lilly's Zepbound.”
“NOVO NORDISK (NVO) shares fell over 15% on Monday after the company’s next-generation obesity drug CagriSema delivered less weight loss than Eli Lilly’s competing treatment in a phase 3 trial, raising new concerns about its sales potential.”
“Novo Nordisk shares fell over 16% on Monday after the company’s next-generation obesity drug CagriSema delivered less weight loss than Eli Lilly’s competing treatment in a phase 3 trial, raising new concerns about its sales potential.”
“after the company’s next-generation obesity drug CagriSema delivered less weight loss than Eli Lilly’s competing treatment in a phase 3 trial, raising new concerns about its sales potential.”
“Novo Nordisk A/S (NYSE:NVO) announced on February 27 that the US Food and Drug Administration approved three new indications for once-weekly Sogroya injection 5 mg, 10 mg, or 15 mg, a long-acting growth hormone, for children aged at least 2.5 years with Idiopathic Short Stature (ISS), short stature born Small for Gestational Age without catch-up growth by the age of 2 years, and growth failure associated with Noonan Syndrome. The approval marks the first long-acting growth hormone supporting children with these three indications in the United States.”
“In another development, Novo Nordisk A/S (NYSE:NVO) and Vivtex Corporation announced on February 25 a partnership for the development of next-generation oral biologic medicines for obesity, diabetes, and associated comorbidities.”
“Eli Lilly reported Phase 3 data showing its oral GLP-1 candidate, orforglipron, produced greater blood sugar and weight reduction in adults with type 2 diabetes than Novo Nordisk’s oral semaglutide.”
“Eli Lilly’s head-to-head Phase 3 win for orforglipron versus Novo Nordisk’s oral semaglutide puts more weight behind its push into oral GLP-1s.”
“Novo Nordisk A/S (NYSE:NVO) and Vivtex Corporation announced on February 25 a partnership for the development of next-generation oral biologic medicines for obesity, diabetes, and associated comorbidities. The terms of the agreement entail that Vivtex would license select oral drug-delivery technologies to Novo Nordisk A/S (NYSE:NVO), with Vivtex eligible to receive upfront consideration, research funding, and milestone payments totalling up to $2.1 billion, and tiered royalties on future product sales.”
“Novo Nordisk A/S (NYSE:NVO) further reported that following research and formulation selection, it will assume responsibility for regulatory activities, global development, manufacturing, and commercialization of any resulting products.”
.jpg&width=160)